An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses.

Autor: Jensen, Sophie B., Jæhger, Ditte E., Serrano-Chávez, Elizabeth, Halldórsdóttir, Hólmfríður R., Engel, Trine B., Jørgensen, Jennifer S., Björgvinsdóttir, Unnur J., Kostrikov, Serhii, Scheeper, Marouschka J., Ringgaard, Lars, Bruun, Linda M., Stavnsbjerg, Camilla, Christensen, Esben, Bak, Martin, Thuroczy, Julianna, Balogh, Lajos, Jensen, Andreas T. I., Melander, Fredrik, Kjaer, Andreas, Henriksen, Jonas R.
Předmět:
Zdroj: Nature Communications; 9/3/2024, Vol. 15 Issue 1, p1-18, 18p
Abstrakt: Cancer curing immune responses against heterogeneous solid cancers require that a coordinated immune activation is initiated in the antigen avid but immunosuppressive tumor microenvironment (TME). The plastic TME, and the poor systemic tolerability of immune activating drugs are, however, fundamental barriers to generating curative anticancer immune responses. Here, we introduce the CarboCell technology to overcome these barriers by forming an intratumoral sustained drug release depot that provides high payloads of immune stimulatory drugs selectively within the TME. The CarboCell thereby induces a hot spot for immune cell training and polarization and further drives and maintains the tumor-draining lymph nodes in an anticancer and immune activated state. Mechanistically, this transforms cancerous tissues, consequently generating systemic anticancer immunoreactivity. CarboCell can be injected through standard thin-needle technologies and has inherent imaging contrast which secure accurate intratumoral positioning. In particular, here we report the therapeutic performance for a dual-drug CarboCell providing sustained release of a Toll-like receptor 7/8 agonist and a transforming growth factor-β inhibitor in preclinical tumor models in female mice. Co-delivery of TLR7/8 agonists and TGF-β inhibitors (TGFβi) has the potential to overcome immunosuppression in the tumor microenvironment. Here the authors describe the application of the CarboCell technology for the sustained intratumoral release of a TLR7/8 agonist alone or in combination with a TGFβi, promoting anti-tumor immune responses in preclinical cancer models. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: